- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03602261
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Peoria, Arizona, United States, 85381
- AKDHC Medical Research Services
-
Phoenix, Arizona, United States, 85035
- AKDHC Medical Research Services
-
Phoenix, Arizona, United States, 85027
- AKDHC Medical Research Services
-
Phoenix, Arizona, United States, 85258
- AKDHC Medical Research Services
-
-
California
-
Cypress, California, United States, 90630
- WCCT Global, Inc.
-
Hacienda Heights, California, United States, 91745
- Hacienda Dialysis Center
-
La Mesa, California, United States, 91942
- California Institute of Renal Research CKD/Dialysis & Transplant Division
-
Long Beach, California, United States, 90807
- Long Beach Quest Dialysis Center
-
Ontario, California, United States, 91762
- Ontario Dialysis Center
-
San Dimas, California, United States, 91773
- North America Research Institute, Inc.
-
Sun Valley, California, United States, 91352
- Laurel Canyon Dialysis, LLC
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver Anschutz Medical Campus
-
-
Illinois
-
Chicago, Illinois, United States, 60643
- Research by Design, LLC
-
Evanston, Illinois, United States, 60201
- NorthShore University Health
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01107
- Renal and Transplant Associates of New England
-
-
Mississippi
-
McComb, Mississippi, United States, 39601
- Southwest MS Nephrology
-
-
Texas
-
Houston, Texas, United States, 77099
- Southwest Houston Research Ltd
-
San Antonio, Texas, United States, 78207
- Kidney & Hypertension Specialists
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Each subject must meet the following criteria to be enrolled into the two cohorts of this study:
- Be at least 18 years of age.
- Be diagnosed with CKD requiring in-center HD tiw for the preceding 6 months, as confirmed by medical history.
Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:
- Serum albumin ≤ 3.0 g/dL; and,
- Serum transaminase (alanine transaminase [ALT], glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or glutamic oxaloacetic transaminase [SGOT]) > 2.5 times the upper limit of normal at screening.
- Be receiving calcimimetic therapy (either etelcalcetide or cinacalcet) and/or calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol) for at least 1 month at the time of screening for enrollment. At least 50% of enrolled subjects will have been receiving calcimimetic therapy.
Exhibit during the initial screening visit:
- Plasma iPTH ≥150 pg/mL and <600 pg/mL if receiving etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol); or
- Plasma iPTH ≥300 pg/mL and <900 pg/mL if not receiving etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analog; and,
- Serum total 25-hydroxyvitamin D <30 ng/mL if not receiving vitamin D supplementation.
- When otherwise confirmed eligible at Visit 1, must forgo any further treatment with etelcalcetide and cinacalcet for the duration of the study and undergo an 8-week washout period.
- When otherwise confirmed eligible at Visit 1, must forgo any further treatment with calcitriol or other 1α-hydroxylated vitamin D analogs or vitamin D supplements for the duration of the study and undergo an 8-week washout period.
Exhibit after the 8-week washout period (if required due to prior use of etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analogs, or vitamin D supplementation):
Cohort 1:
- Plasma iPTH increased by at least 50%; and,
- Plasma iPTH ≥300 pg/mL and <1,200 pg/mL; or,
Cohort 2:
a. Plasma iPTH ≥300 pg/mL and <1,200 pg/mL (approximately half of the subjects will be enrolled in each of these two iPTH strata: ≥300 to <600 and ≥600 to <1,200 pg/mL); and
Cohorts 1 and 2:
- Corrected serum calcium <9.8 mg/dL;
- Serum total 25-hydroxyvitamin D <30 ng/mL; and,
- Serum phosphorus <6.5 mg/dL.
- When otherwise confirmed eligible at Visit 1, if taking more than 1,000 mg per day of elemental calcium, reduce calcium use (to ≤1,000 mg per day) and/or use non-calcium based phosphate binder therapies (as needed) for the duration of the study.
- When otherwise confirmed eligible at Visit 1, if taking bone metabolism therapies that may interfere with study endpoints, must discontinue use of these agents for the duration of the study.
- Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
- Female subjects of childbearing potential must be neither pregnant nor lactating and must have a negative serum beta-human chorionic gonadotropin (b-hCG) pregnancy test at the first screening visit and at other scheduled times.
- All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
- Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a legal representative sign the ICF.
4.3 Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from the study:
- Scheduled kidney transplant or parathyroidectomy.
History (prior 2 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus
≥6.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.
- Receipt of bisphosphonate therapy or other bone modifying treatment (eg, denosumab) within 6 months prior to enrollment.
- Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in the opinion of the investigator may worsen or reduce life expectancy, and/or interfere with participation in the study.
- History of neurological/psychiatric disorder, including psychotic disorder or dementia, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikely.
- Known or suspected hypersensitivity to any of the constituents of the study drugs.
- Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CTAP101 Capsules 300mcg/weekly
CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
|
Capsule, weekly
Other Names:
|
ACTIVE_COMPARATOR: CTAP101 Capsules 600mcg/weekly
CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
|
Capsule, weekly
Other Names:
|
ACTIVE_COMPARATOR: CTAP101 Capsules 900mcg/weekly
CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
|
Capsule, weekly
Other Names:
|
PLACEBO_COMPARATOR: Placebo Capsules weekly
Placebo Oral Capsules/weekly for 26 weeks
|
Capsule, weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of mean plasma intact parathyroid hormone (iPTH)
Time Frame: 26 weeks
|
Change of at least 30% from pre-treatment baseline
|
26 weeks
|
Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0
Time Frame: 32 weeks
|
Detailed information collected for each TEAE will include: AE number, a description of the event, start date, end date or ongoing as of date, outcome, therapy for event
|
32 weeks
|
Maximum Plasma Concentration [Cmax]
Time Frame: 74 weeks
|
Maximum serum concentration of Calcifediol
|
74 weeks
|
Increase mean serum total 25-hydroxyvitamin D
Time Frame: 26 weeks
|
Increase to ≥30 ng/mL
|
26 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urologic Diseases
- Endocrine System Diseases
- Renal Insufficiency
- Nutrition Disorders
- Parathyroid Diseases
- Neoplastic Processes
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperparathyroidism
- Neoplasm Metastasis
- Vitamin D Deficiency
- Hyperparathyroidism, Secondary
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcifediol
Other Study ID Numbers
- CTAP101-CL-2010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Calcifediol Oral Capsule
-
OPKO Health, Inc.CompletedVitamin D Insufficiency | CKD Stage 4 | CKD Stage 3 | Secondary Hyperparathyroidism Due to Renal CausesUnited States
-
Parc de Salut MarHospital Clinic of Barcelona; Universidad Complutense de Madrid; Hospital Universitario... and other collaboratorsNot yet recruitingPulmonary Artery Hypertension | Vitamin d Deficiency
-
University Hospital of North NorwayUniversity of Tromso; Cornell University; The Royal Norwegian Ministry of HealthCompletedPsoriasis | Vitamin D DeficiencyNorway
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated